$FATE
FATE THERAPEUTICS INC Stock $fate

$fate Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000110465913084191 Filed on November 13, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q4
Revenue	$0.00	$209.0K	$643.0K
YoY Change	-100.0%	-60.42%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.870M	$1.980M	$1.280M
YoY Change	46.09%	130.23%
% of Gross Profit
Research & Development	$3.030M	$3.378M	$3.400M
YoY Change	-10.88%	1.9%
% of Gross Profit
Depreciation & Amortization	$130.0K	$140.0K	$160.0K
YoY Change	-18.75%	-6.67%
% of Gross Profit
Operating Expenses	$4.902M	$5.357M	$4.687M
YoY Change	4.59%	28.22%
Operating Profit		-$5.148M
YoY Change		41.04%
Interest Expense	-$840.0K	-$930.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net		-$925.0K	$460.0K
YoY Change		99.78%
Pretax Income	-$5.740M	-$6.070M	-$4.160M
YoY Change	37.98%	47.69%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.739M	-$6.073M	-$4.155M
YoY Change	38.12%	47.65%
Net Earnings / Revenue		-2905.74%	-646.19%
Basic Earnings Per Share
Diluted Earnings Per Share	-$299.6K	-$316.8K	-$212.5K
COMMON SHARES
Basic Shares Outstanding	20.36M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$54.00M	$19.10M	$9.100M
YoY Change	493.41%
Cash & Equivalents	$54.04M	$19.08M	$9.087M
Short-Term Investments
Other Short-Term Assets	$600.0K	$300.0K	$700.0K
YoY Change	-14.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$54.65M	$19.39M	$9.793M
YoY Change	458.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$810.0K	$789.0K	$1.161M
YoY Change	-30.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$2.743M	$100.0K
YoY Change	0.0%
Total Long-Term Assets	$932.0K	$3.654M	$1.283M
YoY Change	-27.36%
TOTAL ASSETS
Total Short-Term Assets	$54.65M	$19.39M	$9.793M
Total Long-Term Assets	$932.0K	$3.654M	$1.283M
Total Assets	$55.58M	$23.04M	$11.08M
YoY Change	401.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$682.0K	$3.700M	$1.228M
YoY Change	-44.46%
Accrued Expenses	$2.039M		$1.040M
YoY Change	96.06%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$3.500M	$0.00
YoY Change
Long-Term Debt Due	$1.732M	$1.971M	$1.941M
YoY Change	-10.77%
Total Short-Term Liabilities	$4.600M	$9.491M	$4.850M
YoY Change	-5.15%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$250.0K	$1.732M
YoY Change	-100.0%
Other Long-Term Liabilities	$100.0K	$3.200M	$800.0K
YoY Change	-87.5%
Total Long-Term Liabilities	$100.0K	$250.0K	$1.732M
YoY Change	-94.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.600M	$9.491M	$4.850M
Total Long-Term Liabilities	$100.0K	$250.0K	$1.732M
Total Liabilities	$4.700M	$9.741M	$6.582M
YoY Change	-28.59%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$20.00K	$1.000K	$1.000K
YoY Change	1900.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$50.85M	-$66.40M	-$52.83M
YoY Change
Total Liabilities & Shareholders Equity	$55.58M	$23.04M	$11.08M
YoY Change	401.83%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q4
OPERATING ACTIVITIES
Net Income	-$5.739M	-$6.073M	-$4.155M
YoY Change	38.12%	47.65%
Depreciation, Depletion And Amortization	$130.0K	$140.0K	$160.0K
YoY Change	-18.75%	-6.67%
Cash From Operating Activities	-$4.570M	-$3.480M	-$3.390M
YoY Change	34.81%	25.63%
INVESTING ACTIVITIES
Capital Expenditures	-$150.0K	-$20.00K	-$300.0K
YoY Change	-50.0%	-94.29%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$10.00K	$0.00
YoY Change
Cash From Investing Activities	-$150.0K	-$20.00K	-$300.0K
YoY Change	-50.0%	-94.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	39.68M	19.17M	7.310M
YoY Change	442.82%	514.42%
NET CHANGE
Cash From Operating Activities	-4.570M	-3.480M	-3.390M
Cash From Investing Activities	-150.0K	-20.00K	-300.0K
Cash From Financing Activities	39.68M	19.17M	7.310M
Net Change In Cash	34.96M	15.67M	3.620M
YoY Change	865.75%	-1682553438208000000.0%
FREE CASH FLOW
Cash From Operating Activities	-$4.570M	-$3.480M	-$3.390M
Capital Expenditures	-$150.0K	-$20.00K	-$300.0K
Free Cash Flow	-$4.420M	-$3.460M	-$3.090M
YoY Change	43.04%	42.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Revenue From Grants RevenueFromGrants	2084000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	5011000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19082000	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	304000	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	19386000	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	789000	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2743000	USD
CY2013Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	122000	USD
CY2013Q3	us-gaap	Assets Assets	23040000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9087000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	706000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	9793000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1161000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	122000	USD
CY2013Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3725000	USD
CY2013Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	45000	USD
CY2013Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3481000	USD
CY2013Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	163000	USD
CY2013Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	1971000	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9491000	USD
CY2013Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	153000	USD
CY2013Q3	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	137000	USD
CY2013Q3	fate	Exchangeable Share Liability Noncurrent ExchangeableShareLiabilityNoncurrent	2885000	USD
CY2013Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	250000	USD
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	56526000	USD
CY2012Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2268000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	63000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	251000	USD
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	184000	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1941000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4850000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	132000	USD
CY2012Q4	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	110000	USD
CY2012Q4	fate	Exchangeable Share Liability Noncurrent ExchangeableShareLiabilityNoncurrent	551000	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1732000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	56526000	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	14367000	USD
CY2013Q3	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	80770000	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	-66402000	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23040000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12789000	USD
CY2012Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	65615000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-52825000	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-4113000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12773000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2382000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15155000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-12.24
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1238567	shares
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11076000	USD
CY2012Q4	us-gaap	Assets Assets	11076000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2013Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
	us-gaap	Contracts Revenue ContractsRevenue	2927000	USD
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1377659	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1377659	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1334115	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1334115	shares
CY2013Q3	us-gaap	Contracts Revenue ContractsRevenue	209000	USD
	us-gaap	Operating Expenses OperatingExpenses	13744000	USD
	us-gaap	Revenue Recognition Milestone Method Factors RevenueRecognitionMilestoneMethodFactors	(i) persuasive evidence that an agreement exists; (ii) delivery of the products and/or services has occurred; (iii) the selling price is fixed or determinable; and (iv) collectibility is reasonably assured
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	209000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3378000	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1979000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	5357000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5148000	USD
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-925000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-6073000	USD
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.81
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1262546	shares
	us-gaap	Contracts Revenue ContractsRevenue	626000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	345000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	971000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8976000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4768000	USD
CY2012Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	68360186	shares
CY2012Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	62200000	shares
CY2013Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	44967690	shares
CY2012Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	44967690	shares
CY2013Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	44967690	shares
CY2012Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	44967690	shares
CY2013Q3	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	58518000	USD
CY2012Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	58518000	USD
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	110000000	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	53955000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28839000	USD
	us-gaap	Operating Expenses OperatingExpenses	82794000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-77783000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2987000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-80770000	USD
CY2012Q3	us-gaap	Contracts Revenue ContractsRevenue	208000	USD
CY2012Q3	us-gaap	Revenue From Grants RevenueFromGrants	320000	USD
CY2012Q3	us-gaap	Sales Revenue Net SalesRevenueNet	528000	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3315000	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	863000	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	4178000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3650000	USD
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-463000	USD
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.51
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1171012	shares
	us-gaap	Contracts Revenue ContractsRevenue	1075000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	952000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	2027000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8596000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2944000	USD
	us-gaap	Operating Expenses OperatingExpenses	11540000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9513000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-571000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-10084000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-9.52
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1059113	shares
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	430000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	106000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	63000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	97000	USD
	us-gaap	Straight Line Rent StraightLineRent	138000	USD
	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	63000	USD
	fate	Fair Value Adjustment Of Exchangeable Shares FairValueAdjustmentOfExchangeableShares	-12000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-35000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-323000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	204000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-363000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9880000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	414000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-414000	USD
	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	205000	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	9166000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	9371000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-923000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	442000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	13000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1169000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	129000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	134000	USD
	us-gaap	Straight Line Rent StraightLineRent	185000	USD
	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	63000	USD
	fate	Fair Value Adjustment Of Exchangeable Shares FairValueAdjustmentOfExchangeableShares	2334000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-21000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-18000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	960000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1350000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10795000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	94000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	6000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-88000	USD
	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	23000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1381000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	23736000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1500000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	20878000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of Estimates</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company’s consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company’s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of equity awards and clinical trial accruals. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</font></p> </div>
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	9995000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2379000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	57000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1938000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	271000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	1156000	USD
	us-gaap	Straight Line Rent StraightLineRent	-198000	USD
	fate	Fair Value Adjustment Of Exchangeable Shares FairValueAdjustmentOfExchangeableShares	2885000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-64000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-135000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-332000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1666000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3618000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-69531000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3511000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	208000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	122000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-3425000	USD
	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	287000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1381000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	32236000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	6400000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4150000	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	58646000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	92038000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	19082000	USD
	fate	Number Of Platforms To Enhance Therapeutic Potential Of Adult Stem Cells NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells	2	item
CY2013Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.154	pure
CY2012Q3	fate	Shares Attributable To Share Based Payment Arrangements Excluded From Weighted Average Number Of Shares Outstanding SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding	166252	shares
	fate	Shares Attributable To Share Based Payment Arrangements Excluded From Weighted Average Number Of Shares Outstanding SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding	184517	shares
CY2013Q3	fate	Shares Attributable To Share Based Payment Arrangements Excluded From Weighted Average Number Of Shares Outstanding SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding	102998	shares
	fate	Shares Attributable To Share Based Payment Arrangements Excluded From Weighted Average Number Of Shares Outstanding SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding	111614	shares
CY2012Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7227388	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7227388	shares
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9456944	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9456944	shares
CY2013Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2013Q3	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2013Q3	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2013Q3	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001434316
CY2013Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2250000	USD
CY2013Q3	us-gaap	Long Term Debt LongTermDebt	2250000	USD
CY2013Q3	fate	Long Term Debt Gross Current LongTermDebtGrossCurrent	2000000	USD
CY2013Q3	fate	Debt Instrument Discount Current DebtInstrumentDiscountCurrent	29000	USD
CY2012Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3750000	USD
CY2012Q4	fate	Debt Instrument Discount Non Current DebtInstrumentDiscountNonCurrent	18000	USD
CY2012Q4	us-gaap	Long Term Debt LongTermDebt	3732000	USD
CY2012Q4	fate	Long Term Debt Gross Current LongTermDebtGrossCurrent	2000000	USD
CY2012Q4	fate	Debt Instrument Discount Current DebtInstrumentDiscountCurrent	59000	USD
CY2013Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	23700000	USD
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	500000	USD
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	900000	USD
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	500000	USD
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	FATE THERAPEUTICS INC
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20357158	shares
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5464000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6387000	USD
CY2012Q4	fate	Repurchase Liability For Unvested Equity Awards Current RepurchaseLiabilityForUnvestedEquityAwardsCurrent	143000	USD
CY2013Q3	fate	Repurchase Liability For Unvested Equity Awards Current RepurchaseLiabilityForUnvestedEquityAwardsCurrent	106000	USD
CY2013Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	20000000	USD
CY2013Q3	fate	Lease Term Extended LeaseTermExtended	P2Y
	fate	Schedule Of Actual And Proforma Balance Sheet Detail ScheduleOfActualAndProformaBalanceSheetDetail	<div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"> <p style="TEXT-INDENT: 22.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The following table summarizes certain actual balance sheet data and pro forma balance sheet data to reflect the activities related to the Company’s IPO noted above, as of September 30, 2013 (in thousands):</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <table style="text-align:left;TEXT-ALIGN: left; WIDTH: 797px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="797"> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">September<br /> 30, 2013</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Pro Forma<br /> September<br /> 30, 2013</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Cash and cash equivalents</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">19,082</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">59,127</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Other assets</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,743</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">—</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accounts payable and accrued expenses</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,725</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,344</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Long-term accrued expenses</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">137</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">79</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Convertible notes, net of discount</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">23,481</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">—</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Preferred stock warrant liability</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">163</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">—</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Exchangeable share liability</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,885</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">—</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Convertible preferred stock</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">56,526</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">—</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Common stock</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Additional paid-in capital</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">14,367</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">136,398</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="65%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Deficit accumulated during the development stage</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(80,770</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(81,024</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="65%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total stockholders’ (deficit) equity</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">(66,402</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">)</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="13%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">55,394</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="424"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="8"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="81"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="19"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="8"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="81"></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none;" width="7"></td></tr></table></div>

Files In Submission

Name	View Source	Status
0001104659-13-084191-index-headers.html	Edgar Link	pending
0001104659-13-084191-index.html	Edgar Link	pending
0001104659-13-084191.txt	Edgar Link	pending
0001104659-13-084191-xbrl.zip	Edgar Link	pending
a13-22691_110q.htm	Edgar Link	pending
a13-22691_1ex31d1.htm	Edgar Link	pending
a13-22691_1ex31d2.htm	Edgar Link	pending
a13-22691_1ex32d1.htm	Edgar Link	pending
a13-22691_1ex32d2.htm	Edgar Link	pending
fate-20130930.xml	Edgar Link	completed
fate-20130930.xsd	Edgar Link	pending
fate-20130930_cal.xml	Edgar Link	unprocessable
fate-20130930_def.xml	Edgar Link	unprocessable
fate-20130930_lab.xml	Edgar Link	unprocessable
fate-20130930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FATE
FATE THERAPEUTICS INC Stock $fate

2013 Q4 Form 10-Q Financial Statement

#000110465913084191 Filed on November 13, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FATE FATE THERAPEUTICS INC Stock $fate

2013 Q4 Form 10-Q Financial Statement

#000110465913084191 Filed on November 13, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FATE
FATE THERAPEUTICS INC Stock $fate